Furosemide
|
|
| Systematic (IUPAC) name |
| 4-chloro-2-(furan-2-ylmethylamino)- 5-sulfamoylbenzoic acid |
| Clinical data |
| Licence data |
US Daily Med:link |
| Pregnancy cat. |
C (AU) C (US) |
| Legal status |
℞ Prescription only |
| Routes |
Oral, IV, IM |
| Pharmacokinetic data |
| Bioavailability |
43-69% |
| Metabolism |
hepatic and renal glucuronidation |
| Half-life |
up to 100 minutes |
| Excretion |
renal 66%, biliary 33% |
| Identifiers |
| CAS number |
54-31-9 Y |
| ATC code |
C03CA01 |
| PubChem |
CID 3440 |
| DrugBank |
DB00695 |
| ChemSpider |
3322 Y |
| UNII |
7LXU5N7ZO5 Y |
| KEGG |
D00331 Y |
| ChEBI |
CHEBI:47426 Y |
| ChEMBL |
CHEMBL35 Y |
| Chemical data |
| Formula |
C12H11ClN2O5S |
| Mol. mass |
330.745 g/mol |
SMILES
- O=S(=O)(N)c1c(Cl)cc(c(C(=O)O)c1)NCc2occc2
|
InChI
-
InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19) Y
Key:ZZUFCTLCJUWOSV-UHFFFAOYSA-N Y
|
Y (what is this?) (verify)
|
Furosemide (INN/BAN[1]) or frusemide (former BAN) is a loop diuretic used in the treatment of congestive heart failure and edema. It is most commonly marketed by Sanofi-Aventis under the brand name Lasix, and also under the brand name Frumex.[2] It has also been used to prevent Thoroughbred and Standardbred race horses from bleeding through the nose during races.
Along with some other diuretics, furosemide is also included on the World Anti-Doping Agency's banned drug list due to its alleged use as a masking agent for other drugs.
|
Contents
- 1 Medical uses
- 2 Adverse effects
- 3 Mechanism of action
- 4 Brand names
- 5 Veterinary uses
- 5.1 Precautions, side effects, and administration for horses
- 6 References
- 7 Further reading
- 8 External links
|
Medical uses
Furosemide is primarily used for the treatment of hypertension and edema.[3] It is the first-line agent in most people with edema due to congestive heart failure.[3] It is also used for hepatic cirrhosis, renal impairment, nephrotic syndrome, in adjunct therapy for cerebral/pulmonary edema where rapid diuresis is required (IV injection), and in the management of severe hypercalcemia in combination with adequate rehydration.[4]
Adverse effects
Although disputed,[5] it is considered ototoxic: "usually with large parenteral doses and rapid administration and in renal impairment".[6] Furosemide also can lead to gout due to hyperuricemia. Hyperglycemia is also a common side effect.
The tendency, as for all loop diuretics, to cause low potassium levels (hypokalemia) has given rise to combination products, either with potassium itself (e.g. Lasix-K) or with the potassium-sparing diuretic amiloride (Co-amilofruse).
Interactions
Furosemide has potential interactions with the following medications:[7]
- Aminoglycoside antibiotics such as gentamicin
- Aspirin and other salicylates
- Other diuretics (e.g. ethacrynic acid, hydrochlorothiazide)
- Indomethacin
- Lithium
- Synergistic effects with other antihypertensives (e.g. doxazosin)
- Sucralfate
Mechanism of action
Main article: Loop diuretic
Furosemide, like other loop diuretics, acts by inhibiting NKCC2, the luminal Na-K-2Cl symporter in the thick ascending limb of the loop of Henle. The action on the distal tubules is independent of any inhibitory effect on carbonic anhydrase or aldosterone; it also abolishes the corticomedullary osmotic gradient and blocks negative, as well as positive, free water clearance.
Due to the large NaCl absorptive capacity of the loop of Henle, diuresis is not limited by development of acidosis, as it is with the carbonic anhydrase inhibitors.
By inhibiting the transporter, the loop diuretics reduce the reabsorption of NaCl and also diminish the lumen-positive potential that derives from K+ recycling. This electrical potential normally drives divalent cation reabsorbtion in the loop, and by reducing this potential, loop diuretics cause an increase in Mg2+ and Ca2+ excretion. Prolonged use can cause significant hypomagnesemia in some patients. Since Ca2+ is actively reabsorbed in the distal convoluted tubule, loop diuretics do not generally cause hypocalcemia.
Additionally, furosemide is a noncompetitive subtype-specific blocker of GABA-A receptors.[8][9][10] Furosemide has been reported to reversibly antagonize GABA-evoked currents of α6β2γ2 receptors at µM concentrations, but not α1β2γ2 receptors.[8][10] During development, the α6β2γ2 receptor increases in expression in cerebellar granule neurons, corresponding to increased sensitivity to furosemide.[9]
Brand names
Some of the brand names under which furosemide is marketed include: Aisemide, Apo-Furosemide, Beronald, Desdemin, Discoid, Diural, Diurapid, Dryptal, Durafurid, Edemid, Errolon, Eutensin, Flusapex, Frudix, Frusetic, Frusid, Fulsix, Fuluvamide, Furesis, Furix, Furo-Puren, Furosedon, Fusid.frusone, Hydro-rapid, Impugan, Katlex, Lasilix, Lasix, Lodix, Lowpston, Macasirool, Mirfat, Nicorol, Odemase, Oedemex, Profemin, Rosemide, Rusyde, Salix, Trofurit, Uremide and Urex. The name Lasix is derived from the phrase "(la)sts (six) (hours)" — referring to its duration of action.[11] Intravenous and oral Lasix lasts two to four hours.[12]
Veterinary uses
The diuretic effects are put to use most commonly in horses to prevent bleeding during a race. Sometime in the early 1970s, furosemide's ability to prevent, or at least greatly reduce, the incidence of bleeding (EIPH) by horses during races was discovered accidentally. In the United States of America, pursuant to the racing rules of most states, horses that bleed from the nostrils three times are permanently barred from racing (for their own protection), these rules do not apply in all countries. Clinical trials followed, and by decade's end, racing commissions in some states in the USA began legalizing its use on race horses. On September 1, 1995, New York became the last state in the United States to approve such use, after years of refusing to consider doing so. Some states allow its use for all racehorses; some allow it only for confirmed "bleeders". However, its use for this purpose is still prohibited in many other countries, and veterinarians dispute its use for this problem.
Furosemide is also used in horses for pulmonary edema, congestive heart failure (in combination with other drugs), and allergic reactions. Despite the fact it increases circulation to the kidneys, it does not help kidney function, and is not recommended for kidney disease.
It is also used to treat congestive heart failure in canines (which experience fluid on the lungs) due to complications from heartworm. It can be used in conjunction with an antibiotic and anti-inflammatory to treat this condition.
Precautions, side effects, and administration for horses
Furosemide is injected either intramuscularly (IM) or intravenously (IV), usually 0.5-1.0 mg/kg twice/day, although less before a horse is raced. As with many diuretics, it can cause dehydration and electrolyte imbalance, including loss of potassium, calcium, sodium, and magnesium. Excessive use of furosemide will most likely lead to a metabolic alkalosis due to hypochloremia and hypokalemia. The drug should, therefore, not be used in horses that are dehydrated or experiencing kidney failure. It should be used with caution in horses with liver problems or electrolyte abnormalities. Overdose may lead to dehydration, change in drinking patterns and urination, seizures, gastrointestinal problems, kidney damage, lethargy, collapse, and coma.
Furosemide should be used with caution when combined with corticosteroids (as this increases the risk of electrolyte imbalance), aminoglycoside antibiotics (increases risk of kidney or ear damage), and trimethoprim sulfa (causes decreased platelet count). It may also cause interactions with anesthesics, so its use should be related to the veterinarian if the animal is going into surgery, and it decreases the kidneys' ability to excrete aspirin, so dosages will need to be adjusted if combined with that drug.
Furosemide may increase the risk of digoxin toxicity due to hypokalemia.
The drug is best not used during pregnancy or in a lactating mare, as it has been shown to be passed through the placenta and milk in studies with other species. It should not be used in horses with pituitary pars intermedia dysfunction (Cushings).
Furosemide is detectable in urine 36–72 hours following injection. Its use is prohibited by most equestrian organizations.
References
- ^ http://www.mhra.gov.uk/Howweregulate/Medicines/Namingofmedicines/ChangestomedicinesnamesBANstorINNs/index.htm
- ^ [1]
- ^ a b "Furosemide". The American Society of Health-System Pharmacists. http://www.drugs.com/monograph/furosemide.html. Retrieved 3 April 2011.
- ^ Rossi S, ed. (2004). Australian Medicines Handbook 2004 (5th ed.). Adelaide, S.A.: Australian Medicines Handbook Pty Ltd. ISBN 0-9578521-4-2. http://www.amh.net.au/.
- ^ Rais-Bahrami K, Majd M, Veszelovszky E, Short B (2004). "Use of furosemide and hearing loss in neonatal intensive care survivors". Am J Perinatol 21 (6): 329–32. doi:10.1055/s-2004-831887. PMID 15311369.
- ^ BNF 45 March 2003
- ^ Brand name:Lasix - Generic name: Furosemide Prescription Drug Information, Side Effects - PDRHealth
- ^ a b Korpi ER, Kuner T, Seeburg PH, Lüddens H (1995). "Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor". Mol. Pharmacology. 47 (2): 283–9. PMID 7870036.
- ^ a b Tia S, Wang JF, Kotchabhakdi N, Vicini S (1996). "Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit". J. Neurosci. 16 (11): 3630–40. PMID 8642407.
- ^ a b Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ (1996). "Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit". Mol. Pharmacol. 50 (3): 670–8. PMID 8794909.
- ^ Sadava, David E.; Heller, H. Craig; Orians, Gordon H. (2006). Life, the science of biology (8th ed.). p. 1105. ISBN 978-0-7167-7671-0.
- ^ (Basic & Clinical Pharmacology, 11e Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor )
Further reading
- Aventis Pharma (1998). Lasix Approved Product Information. Lane Cove: Aventis Pharma Pty Ltd.
- Barbara Forney (2007). Understanding Equine Medications, Revised Edition (Horse Health Care Library). Eclipse Press. ISBN 1-58150-151-X.
External links
- Lasix and horse bleeding
- Furosemide in the Horse (Wind Publications)
- "Diuretics and other masking agents" (PDF) – Part S5 of the World Anti-Doping Agency's 2005 Prohibited List. International Standard.
- U.S. National Library of Medicine: Drug Information Portal - Furosemide
|
Symporter inhibitors
|
|
| Sodium chloride |
- thiazide: Bendroflumethiazide
- Chlorothiazide
- Cyclopenthiazide
- Cyclothiazide
- Hydrochlorothiazide
- Hydroflumethiazide
- Methyclothiazide
- Polythiazide
- Trichlormethiazide
other: Chlorthalidone
- Metolazone
|
|
| Sodium, potassium, chloride |
|
|
|
Antihypertensives: diuretics (C03)
|
|
Sulfonamides
(and etacrynic acid) |
|
CA inhibitors (at PT)
|
|
|
|
Loop (Na-K-Cl at AL)
|
- Furosemide#
- Bumetanide
- Etacrynic acid
- Etozoline
- Muzolimine
- Piretanide
- Tienilic acid
- Torasemide
|
|
|
Thiazides (Na-Cl at DCT,
Calcium-sparing)
|
- Hydrochlorothiazide#
- Bendroflumethiazide
- Hydroflumethiazide
- Chlorothiazide
- Polythiazide
- Trichlormethiazide
- Cyclopenthiazide
- Methyclothiazide
- Cyclothiazide
- Mebutizide
|
|
|
Thiazide-likes (primarily DCT)
|
- Quinethazone
- Clopamide
- Chlortalidone
- Mefruside
- Clofenamide
- Metolazone
- Meticrane
- Xipamide
- Indapamide
- Clorexolone
- Fenquizone
|
|
|
| Potassium-sparing (at CD) |
|
ESC blockers
|
- Amiloride#
- Triamterene
- Benzamil
|
|
|
Aldosterone antagonists
|
- Spironolactone#
- Eplerenone
- Potassium canrenoate
- Canrenone
|
|
|
| Osmotic diuretics (PT, DL) |
|
|
Vasopressin receptor antagonists
(DCT and CD) |
- vaptans: Conivaptan
- Mozavaptan
- Satavaptan
- Tolvaptan
- tetracyclines: Demeclocycline
|
|
| Other |
- mercurial diuretic (Mersalyl, Meralluride)
- Theobromine
- Cicletanine
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
anat (a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot
|
noco/syva/cong/lyvd/tumr, sysi/epon, injr
|
proc, drug (C2s+n/3/4/5/7/8/9)
|
|
|
|
|
GABAergics
|
|
Receptor
ligands |
|
GABAA
|
- Agonists: Main site: Bamaluzole
- Gaboxadol
- Ibotenic acid
- Isoguvacine
- Isonipecotic acid
- Muscimol (Amanita Muscaria)
- Progabide
- SL 75102
- Thiomuscimol
- Tolgabide; Positive allosteric modulators: Alcohols (2M2B, Ethanol, Ethchlorvynol, Methylpentynol
- Barbiturates
- Benzodiazepines
- Carbamates
- Chlormezanone
- Clomethiazole
- Etomidate
- Kavalactones (Kava)
- Loreclezole
- Metomidate
- Neuroactive steroids
- Nonbenzodiazepines (β-Carbolines, Cyclopyrrolones, Imidazopyridines, Pyrazolopyrimidines, etc.)
- Phenols
- Piperidinediones
- Propanidid
- Pyrazolopyridines
- Quinazolinones
- ROD-188
- Skullcap
- Stiripentol
- Valerenic acid (Valerian)
Note: See the GABAA receptor PAMs navbox for a full list of GABAA positive allosteric modulators.
- Antagonists: Main site: Bicuculline
- Gabazine
- Pitrazepin
- Quisqualamine; Negative allosteric modulators: α5IA
- Bilobalide
- Cicutoxin
- Cyclothiazide
- DMCM
- Flumazenil
- Flurothyl
- Furosemide
- Iomazenil (123I)
- L-655,708
- Oenanthotoxin
- Penicillin
- Pentylenetetrazol
- Picrotoxin
- PWZ-029
- Radequinil
- Ro15-4513
- Sarmazenil
- Suritozole
- Terbequinil
- Thujone
- Thiocolchicoside
- ZK-93426
|
|
|
GABAB
|
- Agonists: Main site: 1,4-Butanediol
- Baclofen
- GBL
- GHB
- GHV
- GVL
- Lesogaberan
- Phenibut
- Progabide
- SKF-97,541
- Tolgabide; Positive allosteric modulators: BHF-177
- BHFF
- BSPP
- CGP-7930
- GS-39783
Antagonists: Main site: CGP-35348
- Phaclofen
- Saclofen
- SCH-50911
|
|
|
GABAC
|
- Agonists: Main site: CACA
- CAMP
- GABOB
- N4-Chloroacetylcytosine arabinoside
- Progabide
- Tolgabide
Antagonists: Main site: Bilobalide
- TPMPA
|
|
|
Reuptake
inhibitors |
|
Plasmalemmal
|
|
GAT inhibitors
|
- CI-966
- Deramciclane
- EF-1502
- Gabaculine
- Guvacine
- Nipecotic acid
- NNC 05-2090
- SKF-89976A
- SNAP-5114
- Tiagabine
|
|
|
|
Enzyme
inhibitors |
|
Anabolism
|
|
|
|
Catabolism
|
|
GABA-T inhibitors
|
- 3-Hydrazinopropionic acid
- Aminooxyacetic acid
- Gabaculine
- Isoniazid
- Phenelzine
- Phenylethylidenehydrazine
- Sodium valproate
- Valnoctamide
- Valproate pivoxil
- Valproate semisodium (Divalproex sodium)
- Valproic acid
- Valpromide
- Vigabatrin
|
|
|
|
| Others |
|
Precursors
|
|
|
|
Cofactors
|
- Vitamin B6 (pyridoxine
- pyridoxamine
- pyridoxal phosphate)
|
|
|
Others
|
- Gabapentin
- Hopantenic acid
- Picamilon
- Pregabalin
- L-Theanine
|
|
|
